← Back

Wire · opportunities

Psychedelic Depression Treatments Are Gaining Attention – What Comes Next?

Published

22 November 2026

Topic

opportunities

◆ Sectors

Mental Health

◆ Geography

United States

◆ Source

Read at health.yahoo.com →

◆ Verified

Fusion42 · 22 November 2026 · Fusion42 review

Helus Pharma's psychedelic drug HLP003 showed rapid and durable symptom relief in a Phase 3 trial for major depressive disorder as an add-on to standard antidepressants, with over half of patients reaching remission within six weeks. The drug has FDA Breakthrough Therapy Designation but must still pass safety reviews and address adverse effects before approval.

This Wire brief sits within Fusion42's coverage of Mental Health.

◆ ◆ The Wire takeaway

Psychedelic depression treatments are moving beyond early trials into high-potential therapies that could disrupt daily pill routines. You must act fast to position your product as a safe, supervised alternative before regulators set new clinical standards.

◆ Coverage

1 source · 22 Nov 2026

◆ Related on Wire

◆ Topics

Mental Healthpsychedelic-medicinedepression-treatmentclinical-trialbreakthrough-therapymental-health-care